Impairment of health-related quality of life in patients with chronic hepatitis C is associated with insulin resistance

Journal of Gastroenterology

Volumn 49, Issue 2, 2014, Pages 317-323

  Kuwashiro, Takuya ^a   Mizuta, Toshihiko ^a   Kawaguchi, Yasunori ^a   Iwane, Shinji ^a   Takahashi, Hirokazu ^a   Oza, Noriko ^a   Oeda, Satoshi ^a   Isoda, Hiroshi ^a   Eguchi, Yuichiro ^a   Ozaki, Iwata ^a   Anzai, Keizo ^a   Fujimoto, Kazuma ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis C; Health related quality of life; Insulin resistance

Indexed keywords

GLUCOSE; HEMOGLOBIN; HEPATITIS B SURFACE ANTIGEN; INSULIN; SERUM ALBUMIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HOMEOSTASIS; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MENTAL COMPONENT SUMMARY; MIDDLE AGED; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL COMPONENT SUMMARY; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; SHORT FORM 36; VALIDATION STUDY;

ADULT; AGE FACTORS; AGED; FEMALE; GLUCOSE TOLERANCE TEST; HEALTH STATUS; HEMOGLOBINS; HEPATITIS C, CHRONIC; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SEX FACTORS; YOUNG ADULT;

EID: 84896690742     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0781-6     Document Type: Article

References (42)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558-67.
2. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 1998;27:209-12.
3. Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology. 1999;30:1299-301.
4. Kramer L, Bauer E, Funk G, Hofer H, Jessner W, Steindl-Munda P, et al. Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol. 2002;37:349-54.
5. Strauss E, Dias Teixeira MC. Quality of life in hepatitis C. Liver Int. 2006;26:755-65.
6. Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology. 2007;45:806-16.
7. Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007;46:420-31.
8. Teuber G, Schäfer A, Rimpel J, Paul K, Keicher C, Scheurlen M, et al. Deterioration of health-related quality of life and fatigue in patients with chronic hepatitis C: association with demographic factors, inflammatory activity, and degree of fibrosis. J Hepatol. 2008;49:923-9.
9. Petit JM, Bour JB, Galland-Jos C, Minello A, Verges B, Guiguet M, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol. 2001;35:279-83.
10. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology. 2003;125:1695-704.
11. Camma C, Bruno S, Di Marco V, Di Bona D, Rumi M, Vinci M, et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis. Hepatology. 2006;43:64-71.
12. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol. 2004;165:1499-508.
13. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126:840-8.
14. Shaheen M, Echeverry D, Oblad MG, Montoya MI, Teklehaimanot S, Akhtar AJ. Hepatitis C, metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey [NHANES III]. Diabetes Res Clin Pract. 2007;75:320-6.
15. Imazeki F, Yokosuka O, Fukai K, Kanda T, Kojima H, Saisho H. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients. Liver Int. 2008;28:355-62.
16. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center; 1993.
17. Stewart AL, Hays RD, Ware JE Jr. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care. 1988;26:724-35.
18. Ware JE, Sherboume CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care. 1992;30:473-83.
19. McHomey CA, Ware JE, Raczek AE. The MOS 36-item short-form health survey: II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247-63.
20. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32:40-66.
21. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut. 1999;45:295-300.
22. Van der Plas SM, Hansen BE, De Boer JB, Stijnen T, Passchier J, De Man RA, et al. The Liver Disease Symptom Index 2.0; validation of a disease-specific questionnaire. Qual Life Res. 2004;13:1469-81.
23. Gralnek IM, Hays RD, Kilbourne A, Rosen HR, Keeffe EB, Artinian L, et al. Development and evaluation of the Liver Disease Quality of Life Instrument in persons with advanced, chronic liver disease - the LDQOL 1.0. Am J Gastroenterol. 2000;95:3552-65.
24. Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Summary Scales: a user's manual. Boston: The Health Institute, New England Medical Center; 1994.
25. Fukuhara S, Suzukamo Y. Manual of SF-36v2 Japanese version: Institute for Health Outcomes and Process Evaluation Research, Kyoto; 2004.
26. Aaronson NK, Acquadro C, Alonso J, Apolone G, Bucquet D, Bullinger M, et al. International quality of life assessment (IQOLA) project. Qual Life Res. 1992;1:349-51.
27. Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol. 1998;51:903-12.
28. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol. 1998;51:1037-44.
29. Alberti KG, Zimmer PZ. Definition, diagnosis and classification of diabetes mellitus and its complications Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med. 1998;15:539-53.
30. Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. 1997;35:201-7.
31. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289-93.
32. Conjeevaram HS, Wahed AS, Afdhal N, Howell CD, Everhart JE, Hoofnagle JH, Virahep-C Study Group. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology. 2011;140:469-77.
33. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology. 1999;29:264-70.
34. Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol. 2004;40:675-81.
35. Kawaguchi Y, Mizuta T, Oza N, Takahashi H, Ario K, Yoshimura T, et al. Eradication of hepatitis C virus by interferon improves whole-body insulin resistance and hyperinsulinaemia in patients with chronic hepatitis C. Liver Int. 2009;29:871-7.
36. Lecube A, Hernández C, Genescà J, Simó R. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study. Diabetes Care. 2006;29:1096-101.
37. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patient with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104:788-93.
38. Schlotz W, Ambery P, Syddall HE, Crozier SR, Sayer AA, Cooper C, et al. Specific associations of insulin resistance with impaired health-related quality of life in the Hertfordshire Cohort Study. Qual Life Res. 2007;16:429-36.
39. Tillmann HL, Wiese M, Braun Y, Wiegand J, Tenckhoff S, Mössner J, et al. Quality of life in patients with various liver diseases: patients with HCV show greater mental impairment, while patients with PBC have greater physical impairment. J Viral Hepat. 2011;18:252-61.
40. Spoegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systemic review and quantitative assessment. Hepatology. 2005;41:790-800.
41. Sayer AA, Dennison EM, Syddall HE, Gilbody HJ, Phillips DI, Cooper C. Type 2 diabetes, muscle strength, and impaired physical function: the tip of the iceberg? Diabetes Care. 2005;28:2541-2.
42. Helbling B, Overbeck K, Gonvers JJ, Malinverni R, Dufour JF, Borovicka J, et al. Host-rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection. Gut. 2008;57:1597-603.